Market Forecasts Show Growth Across Pharma Facilities, Biologics Testing, and More

New market forecasts project growth across several life sciences sectors, including tech-enabled pharmaceutical facilities, biologics safety testing, central lab services, life science microscopy devices, and biological safety cabinets, over the coming decade. The Europe tech-enabled pharmaceutical facilities market is projected to grow from USD 3.63 billion in 2025 to USD 13.22 billion by 2035, registering a CAGR of 13.80%, while the global biologics safety testing market is projected to grow from about USD 5.57 billion in 2026 to USD 9.66 billion by 2031 at a CAGR of 11.6%.

The Europe tech-enabled pharmaceutical facilities market is primarily driven by higher demand for automation, AI-driven technologies, and the need for greater efficiency in managing complex biologics. Growth is supported by robotic sampling preparation, automated liquid handling systems, and higher integration of AI-driven analytical software, as well as a shift towards Industry 4.0 standards and Process Analytical Technology. Manufacturing facilities dominated with a 27% market share in 2025, followed by research and development facilities at 19%. By technology, robotics and process automation held a 19% share, the largest of any segment. By application, drug manufacturing (API and formulations) led with 29%, and by end user, pharmaceutical manufacturers (branded and generic) accounted for 35%.

The biologics safety testing market is driven by the growth of advanced modalities such as cell and gene therapies and mRNA products, along with the expanding pipeline of biologics and biosimilars and stringent regulatory requirements. The services segment dominated the market share in 2025, driven by increasing outsourcing to CROs and CDMOs, rising complexity of biologics, and the need for specialized expertise. By application, vaccine safety testing is estimated to be the fastest-growing service application segment. North America accounted for the largest regional share in 2025 with 43%.

The Europe central lab market size accounted for USD 1.11 billion in 2025 and is predicted to reach USD 1.99 billion by 2035, growing at a CAGR of 6% from 2026 to 2035. The market is fueled by a rise in multi-country clinical trials, the fast growth of the biopharmaceutical industry, and a growing need for specialized biomarker testing. Biomarker services held a 39% market share in 2025, and pharmaceutical companies led the end-use segment with a 45% share.

The global life science microscopy devices market size was calculated at USD 2.20 billion in 2025 and is predicted to increase from USD 2.33 billion in 2026 to approximately USD 3.94 billion by 2035, expanding at a CAGR of 6.00%. North America held the largest share of 40% in 2025, while Asia Pacific is expected to witness the fastest growth. The light microscopy segment dominated the market in 2025, and the drug development segment is expected to grow at the fastest rate over the forecast period. AI integration is impacting the market, with algorithms capable of interpreting data on huge quantities of microscopic images in just a few seconds.

The Europe biological safety cabinets market was valued at USD 73.61 million in 2025 and is projected to reach USD 138.31 million by 2034, growing at a CAGR of 7.26%. Growth is driven by increasing investments in life sciences research, rising demand for biosafety infrastructure, and stringent regulatory standards. According to the European Centre for Disease Prevention and Control, over 12,000 high containment laboratories in the EU require certified biological safety cabinets for routine operations. Regulation (EU) 2016/429 on transmissible animal diseases and Directive 2000/54/EC on biological agents at work mandate the use of appropriate containment equipment when handling risk group 2 and above pathogens.